Duchenne Muscular Dystrophy Market to Reach $2.1 Billion, Globally, by 2031 at 4.7% CAGR

Allied Market Research - Seite 2

Based on therapeutic area, the molecular based therapies segment held the highest market share in 2021, accounting for around three-fifths of the global Duchenne muscular dystrophy market, and is estimated to maintain its leadership status throughout the forecast period. In addition, the same segment is projected to manifest the highest CAGR of 5.0% from 2022 to 2031, owing to R & D activities for exon skipping drugs, strong product pipeline and significant product launch by key players. The report also discusses steroid therapy segment.

Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/16015

The hospital pharmacies segment to maintain its lead position during the forecast period

Based on distribution channel, the hospital pharmacies segment accounted for the largest share in 2021, contributing to more than three-fifths of the global Duchenne muscular dystrophy market, and is projected to maintain its lead position during the forecast period. This is owing to significant rise in the number of diagnosis through hospitals. However, the drug store & retail pharmacies segment is expected to portray the largest CAGR of 5.4% from 2022 to 2031, owing to the rise in the approval of drugs and their availability in drug store & retail pharmacies.

North America to maintain its dominance by 2031

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than half of the global Duchenne muscular dystrophy market, and is likely to dominate the market during the forecast period. This is owing to technological advancements in Duchenne muscular dystrophy treatment and presence of key players & robust hospital infrastructure in the region. However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.9% from 2022 to 2031. This is owing to rise in cases of Duchenne muscular dystrophy, approval of drugs, development of healthcare infrastructure, and increase in investments projects in the region.

Leading Market Players: -

• F Hoffmann-La Roche AG
• FibroGen, Inc
• GlaxoSmithKline plc
• Italfarmaco S.p.A.
• Nippon Shinyaku Co., Ltd
• Pfizer Inc.
• PTC Therapeutics
• Santhera Pharmaceuticals Inc
• Sarepta therapeutics
• Wave life sciences ltd.

Trending Reports in Healthcare Industry (Book Now with 10% Discount):